To avoid DTC dips and communication snafus, pharma marketing shifts amid COVID-19 crisis
Pharma marketing, like the rest of the ad industry, is in a state of flux brought on by the COVID-19 pandemic. Concerns and debates are swirling around whether drug ads should scale back, if drugmakers should change messaging to be more serious or if they should delay...
Trump tries to lure CureVac to make a ‘U.S. vaccine,’ but German government steps in
It’s a pretty extraordinary story that started off with a CEO exiting a biotech and has now become about the U.S. president allegedly wanting to lure that biotech over to the U.S. to build a vaccine for the coronavirus—but just for Americans. Maybe it was...
States reject drug wholesalers’ $18B opioid settlement offer: WSJ
After years of opioid litigation and a multibillion-dollar settlement offer from the nation’s top drug distributors, nearly two dozen U.S. states have rejected their proposal, The Wall Street Journal reports. Twenty-one state attorneys general sent a letter to...
Concern for drug shortages grows as COVID-19 outbreak drags on
Some drugmakers in China restarted production this week after an extended break for the Chinese New Year, but as the COVID-19 outbreak drags on, governments are trying to get a handle on whether it will result in drug shortages and whether there is anything they can...
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
Drug pricing remains a hot topic, and a new report offers some reasons: The most expensive drugs sold at pharmacies can cost as much as a luxury car—every month. And GoodRx’s latest ranking of the country’s costliest drugs include brands new and old....LATEST NEWS
More anti-epidemic measures eased today
Bulgaria resumes the “green corridor” walk-in vaccination scheme
30,000 Bulgarians receive jabs against Covid-19 in last three days
CureVac’s mRNA coronavirus shot boasts one advantage over Pfizer and Moderna counterparts—refrigerated storage
COVID-19 vaccine players will split $100B in sales and $40B in profits, with Moderna leading the way: analyst